Pacritinib w/ Talazoparib in Pts w/ Myeloproliferative Neoplasms Unresponsive to JAK2 Inhibition | ClinicalTrials HQ

Ask about research services

Swipe the table sideways for more columns.

Trial	Conditions	Status	Phase	Updated	More info	NCT ID
Pacritinib w/ Talazoparib in Pts w/ Myeloproliferative Neoplasms Unresponsive to JAK2 Inhibition	Chronic Disease, Disease Attributes, Hemic and Lymphatic Diseases, Myeloproliferative Disorders, Neoplasms by Histologic Type, Neoplasms by Site, Pathologic Processes, Pathological Conditions, Signs and Symptoms, acquired polycythemia vera, blood coagulation disease, blood platelet disease, bone marrow disorder, bone marrow neoplasm, chronic myelomonocytic leukemia, essential thrombocythemia, hematologic disorder, hematopoietic and lymphoid system neoplasm, hemorrhagic disease, leukemia, myelodysplastic/myeloproliferative disease, myeloid leukemia, neoplasm, primary myelofibrosis, thrombocytosis disease	Recruiting	Phase 1	2024-05-03		NCT06218628

1 results · Page 1 of 1

Swipe the table sideways for more columns.

Organizations	Linked trials
Fox Chase Cancer Center	58

1 results · Page 1 of 1

Swipe the table sideways for more columns.

Research sites	City	Country	Linked trials
Fox Chase Cancer Center - Philadelphia	Philadelphia	United States	10